Variant · Fusion
ABL2 Fusion
CI-VAR-00001316Explore in graph →CIViC 3526
Curated evidence
Evidence by cancer (8 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27125982
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| B Lymphoblastic Leukemia/Lymphoma5 | ||||||||
| RCSD1::ABL2 Fusion | (oncogenic) | Oncogenic | C | N/A N/A | 3 | rejected | civic | |
| RCSD1::ABL2 Fusion | (oncogenic) | Oncogenic | C | Supports Oncogenicity | 3 | submitted | EID9768In a cohort Dutch/German patients (age <15 years) with B cell precursor acute lymphoblastic leukemia, 14 tyrosine kinase fusions were identified among 77 BCR-ABL1-like cases, and zero were identified … (full text at CIViC) PMID 27894077 · Boer et al., 2017 · Open in CIViC | civic |
| RCSD1::ABL2 Fusion | (oncogenic) | Oncogenic | ||||||
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available